Top

Published in:

16-04-2021 | Cardiac Amyloidosis | Original Article

Cardiac amyloidosis characterization by kinetic model fitting on [18F]florbetaben PET images

Authors: M. F. Santarelli, MF, PhD, D. Genovesi, MD, M. Scipioni, V. Positano, MSc, B. Favilli, MSc, A. Giorgetti, MD, G. Vergaro, MD, L. Landini, M. Emdin, MD, PhD, P. Marzullo, MD

Published in: Journal of Nuclear Cardiology | Issue 4/2022

Abstract

Objective

To evaluate the feasibility of kinetic modeling-based approaches from [18F]-Flobetaben dynamic PET images as a non-invasive diagnostic method for cardiac amyloidosis (CA) and to identify the two AL- and ATTR-subtypes.

Methods and Results

Twenty-one patients with diagnoses of CA (11 patients with AL-subtype and 10 patients with ATTR-subtype of CA) and 15 Control patients with no-CA conditions underwent PET/CT imaging after [18F]Florbetaben bolus injection. A two-tissue-compartment (2TC) kinetic model was fitted to time-activity curves (TAC) obtained from left ventricle wall and left atrium cavity ROIs to estimate kinetic micro- and macro-parameters. Combinations of kinetic parameters were evaluated with the purpose of distinguishing Control subjects and CA patients, and to correctly label the last ones as AL- or ATTR-subtype. Resulting sensitivity, specificity, and accuracy for Control subjects were: 0.87, 0.9, 0.89; as far as CA patients, the sensitivity, specificity, and accuracy were respectively 0.9, 1, and 0.97 for AL-CA patients and 0.9, 0.92, 0.97 for ATTR-CA patients.

Conclusion

Pharmacokinetic analysis based on a 2TC model allows cardiac amyloidosis characterization from dynamic [18F]Florbetaben PET images. Estimated model parameters allows to not only distinguish between Control subjects and patients, but also between AL- and ATTR-amyloid patients.

Available only for authorised users

Falk RH, Dubrey SW. Amyloid heart disease. Prog Cardiovasc Dis. 2010;52:347-61.CrossRef

Alexander KM, Singh A, Falk RH. Novel pharmacotherapies for cardiac amyloidosis. Pharmacol Ther. 2017;180:129-38. https://doi.org/10.1016/j.pharmthera.2017.06.011.CrossRefPubMedPubMedCentral

Falk RH. Cardiac amyloidosis: A treatable disease, often overlooked. Circulation. 2011;124:1079-85.CrossRef

Merlini G, Dispenzieri A, Sanchorawala V, Schönland SO, Palladini G, Hawkins PN, Gertz MA. Systemic immunoglobulin light chain amyloidosis. Nat Rev Dis Primers. 2018;4(1):38. https://doi.org/10.1038/s41572-018-0034-3.CrossRefPubMed

Wechalekar AD, Schonland SO, Kastritis E, Gillmore JD, Dimopoulos MA, Lane T, Foli A, Foard D, Milani P, Rannigan L, Hegenbart U, Hawkins PN, Merlini G, Palladini G. A European collaborative study of treatment outcomes in 346 patients with cardiac stage III AL amyloidosis. Blood. 2013;121(17):3420-7. https://doi.org/10.1182/blood-2012-12-473066.CrossRefPubMed

González-López E, Gallego-Delgado M, Guzzo-Merello G, de Haro-Del Moral FJ, Cobo-Marcos M, Robles C, Bornstein B, Salas C, Lara-Pezzi E, Alonso-Pulpon L, Garcia-Pavia P. Wild-type transthyretin amyloidosis as a cause of heart failure with preserved ejection fraction. Eur Heart J. 2015;36(38):2585-94. https://doi.org/10.1093/eurheartj/ehv338.CrossRefPubMed

Skinner M, Sanchorawala V, Seldin DC, Dember LM, Falk RH, Berk JL, et al. High-dose melphalan and autologous stem-cell transplantation in patients with AL amyloidosis: An 8-year study. Ann Intern Med. 2004;140:85-93.CrossRef

Ruberg FL, Berk JL. Transthyretin (ATTR) cardiac amyloidosis. Circulation. 2012;126:1286-300.CrossRef

Gertz MA, Lacy MQ, Dispenzieri A, Hayman SR. Amyloidosis: Diagnosis and management. Clin Lymph, Myel Leuk. 2005;6:208-19. https://doi.org/10.3816/CLM.2005.CrossRef

10.

Kim YJ, Kim HK, Sohn DW, Park JB, Grogan M, Lee SP. Contemporary imaging diagnosis of cardiac amyloidosis. J Cardiovasc Imaging. 2019;27:1. https://doi.org/10.4250/jcvi.2019.27.e9.CrossRefPubMedPubMedCentral

11.

Kim YJ, Ha S, Kim Y. Cardiac amyloidosis imaging with amyloid positron emission tomography: A systematic review and meta-analysis. J Nucl Cardiol. 2020;27(1):123-32. https://doi.org/10.1007/s12350-018-1365-x.CrossRefPubMed

12.

Kircher M, Ihne S, Brumberg J, Morbach C, Knop S, Kortüm KM, et al. Detection of cardiac amyloidosis with 18 F-Florbetaben-PET/CT in comparison to echocardiography, cardiac MRI and DPD-scintigraphy. Eur J Nucl Med Mol Imaging. 2019;46(7):1407-16. https://doi.org/10.1007/s00259-019-04290-y.CrossRefPubMed

13.

Bhogal S, Ladia V, Sitwala P, Cook E, Bajaj K, Ramu V, et al. Cardiac amyloidosis: An updated review with emphasis on diagnosis and future directions. Curr Probl Cardiol. 2018;43(1):10-34. https://doi.org/10.1016/j.cpcardiol.2017.04.003.CrossRefPubMed

14.

Santarelli MF, Genovesi D, Positano V, Di Sarlo R, Scipioni M, Giorgetti A, Landini L, Marzullo P. Cardiac amyloidosis detection by early bisphosphonate (99mTc-HMDP) scintigraphy. J Nucl Cardiol. 2020. https://doi.org/10.1007/s12350-020-02239-5.CrossRefPubMed

15.

Genovesi D, Vergaro G, Emdin M, Giorgetti A, Marzullo P. PET-CT evaluation of amyloid systemic involvement with [18F]-florbetaben in patient with proved cardiac amyloidosis: A case report. J Nucl Cardiol. 2017;24(6):2025-9. https://doi.org/10.1007/s12350-017-0856-5.CrossRefPubMed

16.

Santarelli MF, Scipioni M, Genovesi D, Giorgetti A, Marzullo P, Landini L. Imaging techniques as an aid in the early detection of cardiac amyloidosis. Curr Pharm Des. 2020. https://doi.org/10.2174/1381612826666200813133557.CrossRef

17.

Di Bella G, Pizzino F, Minutoli F, et al. The mosaic of the cardiac amyloidosis diagnosis: Role of imaging insubtypes and stages of the disease. Eur Heart J Cardiovasc Imaging. 2014;15(12):1307-15. https://doi.org/10.1093/ehjci/jeu158.CrossRefPubMed

18.

Kyriakou P, Mouselimis D, Tsarouchas A, Rigopoulos A, Bakogiannis C, Noutsias M, Vassilikos V. Diagnosis of cardiac amyloidosis: A systematic review on the role of imaging and biomarkers. BMC Cardiovasc Disord. 2018;18(1):221.CrossRef

19.

Cappelli F, Gallini C, DiMario C, Costanzo EN, Vaggelli L, Tutino F, et al. Accuracy of 99mTc-hydroxymethylene diphosphonate scintigraphy for diagnosis of transthyretin cardiac amyloidosis. J Nucl Cardiol. 2019;26:497-504.CrossRef

20.

Treglia G, Glaudemans AWJM, Bertagna F, Hazenberg BPC, Erba PA, Giubbini R, et al. Diagnostic accuracy of bone scintigraphy in the assessment of cardiac transthyretin-related amyloidosis: A bivariate meta-analysis. Eur J Nuclear Med Mol Imaging. 2018;45:1945-55.CrossRef

21.

Bokhari S, Castaño A, Pozniakoff T, Deslisle S, Latif F, Maurer MS. 99mTc-pyrophosphate scintigraphy for differentiating light-chain cardiac amyloidosis from the transthyretin-related familial and senile cardiac amyloidoses. Circ Cardiovasc Imaging. 2013;6(2):195-201.CrossRef

22.

Law WP, Moore PT, Ng ACT, Wang WYS, Mollee PN. Cardiac amyloid imaging with 18F-florbetaben PET: A pilot study. J Nucl Med. 2016;57(11):1733-9. https://doi.org/10.2967/jnumed.115.169870.CrossRefPubMed

23.

Dorbala S, Vangala D, Seme J, Strader C, Bruyere JR, Di Carli MF, et al. Imaging cardiac amyloidosis: A pilot study using 18F-florbetapir positron emission tomography. Eur J Nucl Med Mol Imaging. 2014;41(9):1652-62. https://doi.org/10.1007/s00259-014-2787-6.CrossRefPubMed

24.

Osborne DR, Acuff SN, Stuckey A, Wall JS. A routine PET/CT protocol with streamlined calculations for assessing cardiac amyloidosis using 18F-florbetapir. Frontiers Cardiovasc Med. 2015;2:1-9. https://doi.org/10.3389/fcvm.2015.00023.CrossRef

25.

Kero T, Sörensen J, Antoni G, Wilking H, Carlson K, Vedin O, et al. Quantification of 11C-PIB kinetics in cardiac amyloidosis. J Nucl Cardiol. 2018. https://doi.org/10.1007/s12350-018-1349-x.CrossRefPubMedPubMedCentral

26.

Genovesi D, Vergaro G, Giorgetti A, Marzullo P, Scipioni M, Santarelli MF, Pucci A, Buda G, Volpi E, Emdin M. [18F]-Florbetaben PET/CT for differential diagnosis among cardiac immunoglobulin light chain, transthyretin amyloidosis, and mimicking conditions. J Am Coll Cardiol Imaging. 2020. https://doi.org/10.1016/j.jcmg.2020.05.031.CrossRef

27.

Gillmore JD, et al. BCSH Committee. Guidelines on the diagnosis ad investigation of AL amyloidosis. Br J Haematol. 2015;168:2017-218.CrossRef

28.

Bentourkia M, Zaidi H. Tracer kinetic modeling in PET. PET Clin. 2007;2(2):267-77. https://doi.org/10.1016/j.cpet.2007.08.003.CrossRefPubMed

29.

Becker GA, Ichise M, Barthel H, Luthardt J, Patt M, Seese A, et al. PET quantification of 18F-florbetaben binding to amyloid deposits in human brains. J Nucl Med. 2013;54(5):723-31. https://doi.org/10.2967/jnumed.112.107185.CrossRefPubMed

30.

Scipioni M, Giorgetti A, Della Latta D, Fucci S, Positano V, Landini L, Santarelli MF. Accelerated PET kinetic maps estimation by analytic fitting method. Comput Biol Med. 2018;99:221-35.CrossRef

31.

Gunn RN, Gunn SR, Cunningham VJ. Positron emission tomography compartmental models. J Cereb Blood Flow Metab. 2001;21:635-52. https://doi.org/10.1097/00004647-200106000-00002.CrossRefPubMed

32.

Burnham KP, Anderson DR. Model selection and multimodel inference: A practical information theoretic approach. 2nd ed. New York: Springer-Verlag; 2002. p. 70-5.

33.

Arlot Sylvain, Celisse Alain. A survey of cross-validation procedures for model selection. Stat. Surv. 2010;4:40-79. https://doi.org/10.1214/09-ss054.CrossRef

34.

Senda M, Sasaki M, Yamane T, Shimizu K, Patt M, Barthel H, et al. Ethnic comparison of pharmacokinetics of 18F-florbetaben, a PET tracer for beta-amyloid imaging, in healthy Caucasian and Japanese subjects. Eur J Nucl Med Mol Imaging. 2015;42(1):89-96. https://doi.org/10.1007/s00259-014-2890-8.CrossRefPubMed

35.

Giorgetti A, Genovesi D, Emdin M. Cardiac amyloidosis: The starched heart. J Nucl Cardiol. 2018. https://doi.org/10.1007/s12350-018-1399-0.CrossRefPubMed

36.

Gillmore JD, et al. Nonbiopsy diagnosis of cardiac transthyretine amyloidosis. Circulation. 2016;133:2404-12.CrossRef

Title: Cardiac amyloidosis characterization by kinetic model fitting on [18F]florbetaben PET images
Authors: M. F. Santarelli, MF, PhD
D. Genovesi, MD
M. Scipioni
V. Positano, MSc
B. Favilli, MSc
A. Giorgetti, MD
G. Vergaro, MD
L. Landini
M. Emdin, MD, PhD
P. Marzullo, MD
Publication date: 16-04-2021
Publisher: Springer International Publishing
Keywords: Cardiac Amyloidosis
Amyloidosis
Published in: Journal of Nuclear Cardiology / Issue 4/2022
Print ISSN: 1071-3581
Electronic ISSN: 1532-6551
DOI: https://doi.org/10.1007/s12350-021-02608-8

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Cardiac amyloidosis characterization by kinetic model fitting on [18F]florbetaben PET images

Abstract

Objective

Methods and Results

Conclusion

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Objective

Methods and Results

Conclusion

Please log in to get access to this content

Other articles of this Issue 4/2022

Investigating vascular diseases in people living with HIV by nuclear imaging

Effect of temporal sampling protocols on myocardial blood flow measurements using Rubidium-82 PET

Serial Tc-99m MDP scintigraphy demonstrating increasing cardiac uptake over time in a patient with light-chain cardiac amyloidosis

Intravenous insulin injection supplemented with subsequent milk consumption is a safer formulation for cardiac viability 18F-FDG imaging

Tc-99m HMDP bone scintigraphy for cardiac amyloidosis diagnosis: A false positive case

18F-FDG PET/CT detected mediastinal small-cell neuroendocrine carcinoma with all cardiac cavities metastases